The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 14, 2020

Filed:

Feb. 11, 2019
Applicants:

Cerecor, Inc., Baltimore, MD (US);

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Inventors:

Reza Mazhari, Towson, MD (US);

Djelila Mezaache, Stone Ridge, VA (US);

Blake M. Paterson, Baltimore, MD (US);

James Vornov, Pikesville, MD (US);

Rachel M. Garner, Baltimore, MD (US);

Todd Nelson, Cream Ridge, NJ (US);

Assignees:

Cerecor Inc., Rockville, MD (US);

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/12 (2006.01); A61P 9/10 (2006.01); A61P 9/00 (2006.01); A61P 5/24 (2006.01); A61P 43/00 (2006.01); A61P 29/02 (2006.01); A61P 27/16 (2006.01); A61P 27/06 (2006.01); A61P 25/28 (2006.01); A61P 25/24 (2006.01); A61P 25/18 (2006.01); A61P 25/16 (2006.01); A61P 25/14 (2006.01); A61P 25/08 (2006.01); A61P 25/04 (2006.01); A61P 25/00 (2006.01); A61P 17/02 (2006.01); A61P 15/00 (2006.01); A61P 11/14 (2006.01);
U.S. Cl.
CPC ...
C07D 401/12 (2013.01);
Abstract

The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.


Find Patent Forward Citations

Loading…